Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Open Access
- 1 May 2012
- journal article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 1 (3), 393-395
- https://doi.org/10.4161/onci.19070
Abstract
The efficacy of antineoplastic chemotherapies with anthracyclines or oxaliplatin relies on the induction of immunogenic cell death, thus provoking an anticancer immune response. Recently, we observed that overexpression of CD39, an ATP-degrading enzyme expressed on the cell surface, abolishes the immunogenicity of cell death, thus rendering cancers resistant against chemotherapy.Keywords
This publication has 10 references indexed in Scilit:
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in MiceScience, 2011
- CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic LeukemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine ProductionThe Journal of Immunology, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in MiceGastroenterology, 2010
- Extracellular adenosine triphosphate and adenosine in cancerOncogene, 2010
- Chemotherapy induces ATP release from tumor cellsCell Cycle, 2009
- Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck CancerClinical Cancer Research, 2009
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumorsNature Medicine, 2009
- Metabolic Control of Excessive Extracellular Nucleotide Accumulation by CD39/Ecto-Nucleotidase-1: Implications for Ischemic Vascular DiseasesThe Journal of pharmacology and experimental therapeutics, 2003